Trimethoprim-polymyxin B ophthalmic solution in the treatment of presumptive bacterial conjunctivitis--a multicentre trial of its efficacy versus neomycin-polymyxin B-gramicidin and chloramphenicol ophthalmic solutions.

Abstract

Two-hundred and thirty patients with a diagnosis of presumptive bacterial conjunctivitis were assessed in a randomized double-blind multicentre trial. In two of the centres the patients had been treated with either trimethoprim-polymyxin B or neomycin-polymyxin B-gramicidin ophthalmic solution. In the other two centres the patients had been treated with either trimethoprim-polymyxin B or chloramphenicol ophthalmic solution. All of the preparations used were shown to be effective and very few adverse reactions were encountered. No significant difference in clinical efficacy could be demonstrated between trimethoprim-polymyxin B and neomycin-polymyxin B -gramicidin but trimethoprim-polymyxin B was found to be significantly better (P = 0.03) than chloramphenicol in reducing signs and symptoms.

• Authors: J R Gibson
• Journal: The Journal of antimicrobial chemotherapy (J Antimicrob Chemother) Vol. 11 Issue 3 Pg. 217-21 (Mar 1983) ISSN: 0305-7453 [Print] England
• PMID: 6188739 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)

Chemical References

• Drug Combinations
• Ophthalmic Solutions
• Polymyxins
• Gramicidin
• Chloramphenicol
• Trimethoprim
• Neomycin
• Polymyxin B

Topics

• Chloramphenicol (therapeutic use)
• Conjunctivitis (drug therapy)
• Double-Blind Method
• Drug Combinations
• Gramicidin (therapeutic use)
• Humans
• Neomycin (therapeutic use)
• Ophthalmic Solutions
• Polymyxin B (administration & dosage, therapeutic use)
• Polymyxins (therapeutic use)
• Trimethoprim (administration & dosage, therapeutic use)